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Background: This study aimed to evaluate the relationship between tricuspid annular dilatation (TAD) and tricus-
pid regurgitation (TR), and the prognostic value of TAD using three-dimensional transesophageal echocardiogra-
phy (3D TEE).
Methods: Tricuspid annular area (TAA) was measured in 116 patients using 3D TEE. Patients were classiﬁed into
three groups (mild TR: n= 77,moderate TR: n= 26, severe TR: n= 13).Moreover, patients were classiﬁed into
two groups based on rehospitalization for heart failure (HF); HF (+) group (n=18) andHF (−) group (n=98).
Results: TAA in the severe TR groupwas signiﬁcantly larger than that in themild andmoderate TR groups (18.4±
3.8 cm2 vs. 11.7±3.2 cm2, 12.3±3.4 cm2, p b 0.05). TAA in theHF (+) groupwas signiﬁcantly larger than that in
the HF (−) group (16.8 ± 4.3 cm2 vs. 11.8 ± 3.3 cm2, p b 0.001). In receiver operating characteristics curve
assessing the ability of TAA to predict hospitalization for HF, the area under the curve was 0.84. TAA ≥ 15 cm2
best predicted hospitalization for HFwith 77.8% sensitivity and 84.6% speciﬁcity. The incidence of hospitalization
for HF during 3 years was signiﬁcantly higher in the TAD (+) group (TAA ≥ 15 cm2) than the TAD (−) group
(48.3% vs 4.6%, p b 0.001).
Conclusions: The results of this study suggested a possible association between TAD and the TR severity. TAD
estimated using 3D TEE may predict hospitalization for prospective HF.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Functional tricuspid regurgitation (TR) with no deformation of the
tricuspid valve (TV) commonly occurs in patients with left-sided valve
disease and left ventricular (LV) dysfunction. TR severity can consider-
ably inﬂuence long-term outcome [1]. Several studies have suggested
that changes in TV geometry in patients with functional TR, including
annular dilatation and tethering of the leaﬂets, might gradually and
negatively inﬂuence TR [2]. The tricuspid annulus (TA) is a component
of both the TV and right ventricle (RV). Both the RV and TA must be di-
lated for surgery to be indicated [2,3]. Because high postoperative mor-
bidity and mortality are associated with TR [4], tricuspid annuloplasty
(TAP) for functional TR is recommended in patients with left-sidedeliability and freedom from bias
ascular Medicine, Hiroshima
ences, Hiroshima, Japan, 1-2-3,
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d Ltd. This is an open access article unheart disease. However, residual regurgitation often persists after TAP
[4–8]. These unsatisfactory results may be related to an incomplete
knowledge of TA dilatation (TAD). Preoperative evaluation of TV
using two-dimensional (2D) echocardiography is difﬁcult. Recently,
three-dimensional transesophageal echocardiography (3D TEE) was
developed to provide superior image quality. Studies have revealed
the advantages of this modality for assessing LV volume, mass, and out-
put [9–11] and elucidating the 3D geometry of the mitral valve and
annulus [12]. In this study, 3D TEEwas utilized to provide fast, noninva-
sive, and accurate estimations of TV morphology. The purpose of this
study was to evaluate the relationship between TAD and TR, and the
prognostic value of TAD by 3D TEE.
2. Materials and Methods
2.1. Study patients and transthoracic echocardiography
We performed a retrospective analysis of 144 consecutive patients
in whom 3D TEE was performed at Hiroshima City Hospital from April
2009 to April 2011. Among these, patients in whom 3D TEE wasder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ography (2D TTE) and was not accompanied with congenital heart dis-
ease were enrolled in this study. All patients included in this study had
functional TR. There were no patients with organic TR in whom TV de-
formation or ﬂail motion was detected, those in whom previous TAP
or TV repair had been performed or those with pacemaker wires across
the TV. For patients with heart failure (HF), 3D TEE was performed after
stabilization of hemodynamic conditions, treatment with intravenous
and oral drugs, and full recovery, to exclude the inﬂuence of volume
and pressure overload on TR. Estimated glomerular ﬁltration rate was
calculated using the Japanese equations for estimating glomerular
ﬁltration rate from serum creatinine; patients were diagnosed with
CKD if glomerular ﬁltration rate was b60 ml/min per 1.73 m2. TTE was
performed using i33 instruments (Philips Technology, Amsterdam,
The Netherlands). Images were obtained after the gain, compression
controls, and timegain compensation settingswere optimized to ensure
image quality. Left atrial and ventricular diametersweremeasured from
M-mode tracing. Left ventricular ejection fraction (LVEF) and right ven-
tricular ejection fraction (RVEF) were obtained by Simpson’s method
using apical 2- and 4-chamber views. LV and RV dysfunctions were de-
ﬁned as ejection fraction≤ 40% [13]. TA dimensionswere deﬁned as the
distance between the insertion sites of septal and anterior TV leaﬂets
and obtained at an end-diastolic still frame using the apical 4-chamber
view. Right ventricular end-diastolic dimension (RVDd) and right
ventricular end-systolic dimension (RVDs)were obtained using the api-
cal 4-chamber view. Using 2D Doppler echocardiography, pulmonary
artery systolic pressure (PASP) was estimated from the TR jet velocity
using a modiﬁed Bernoulli equation: 4 × (velocity)2 + right atrial
pressure [13,14]. Right atrial pressure was estimated at 5 mmHg if the
inferior vena cava (IVC)was not dilated (b1.7 cm) and the diameter de-
creased by 50% during inspiration, at 10 mmHg if the IVC was dilated
with normal inspiratory collapse, and at 15mmHg if the IVCwas dilated
and did not collapsewith inspiration [15]. The severity of TRwas graded
as follows: mild, moderate and severe based on 2D TTE ﬁndings of
regurgitation on color Doppler (jet vena contracta, PISA radius,
regurgitant oriﬁce area, and the relative size of the regurgitant jet)
using the apical 4-chamber view and hepatic venous ﬂow pattern
[16]. Patients were classiﬁed into three groups according to TR grade.
All parameters were assessed and compared among the three groups.
Moreover, patients were classiﬁed into two groups based on rehospital-
ization for HF after discharge from the hospital. Clinical follow-up was
performed for up to 3 years.
2.2. 3D TEE analysis
3D TEEwas performedwithin 48h after 2DTTE using an iE33 system
with an X7-2 t transducer (2–7 MHz) (Philips Technology). First, a 2D
TEE image of the TVwas obtained, and the best imagewith a good echo-
cardiographic signal and a clear R-wave was utilized (Fig. 1A). It was
taken at an angle of 45° in most cases. Second, full-volume imaging
was performed at the same angle (Fig. 1B) and analyzed using the
QLAB software. In Fig. 1C, the yellow frame was full-volume imaging.
Short-axis plane of TV was obtained in the blue frame referring to full-
volume imaging. In the cross-sectional image with blue frame, the red
linewas adjusted from the anteroseptal to the anteroposterior commis-
sure, and the green linewas adjusted vertical thinning from the anterior
intercommissure to the posteroseptal commissure; thewhite dots were
the three commissures. In the green and red frames, the blue line was
adjusted at TV annulus. The TV in the cross-sectional image in the blue
frame was measured in the end systolic phase (Fig. 1D). The tricuspid
annular area (TAA) and 3 intercommissural distances (ICDs) (anterior,
posterior, and septal ICD) were measured (Fig. 1E). Interobserver and
intraobserver variability in TV measurement was determined by analy-
sis of 10 random 3D images by 2 independent blinded observers and by
the same observer at 2 different times. Informed consent was obtained
from all patients. The study protocol conforms to the ethical guidelinesof the 1975 Declaration of Helsinki as reﬂected in a priori approval by
the ethical committee of Hiroshima City Hospital.
2.3. Statistical analysis
Standard statistical methods were used in this study. Signiﬁcant dif-
ferenceswere tested using the χ2 test for categorical variables. Normally
distributed continuous variables are presented as mean and standard
deviation (SD) or median and inter-quartile range (IQR). Unpaired
Student’s t test or Wilcoxon rank-sum test when appropriate was
used for continuous variables. Kruskal–Wallis testwas used for compar-
ingmore than two groups and post-hoc analyses were performed using
Steel–Dwass’s multiple comparison test. Event-free survival curves up
to 3 years after 3D TEEwere constructed using the Kaplan–Meiermeth-
od andwere compared using the log-rank test. Cox proportional hazard
regressionwas used to identify independent predictors of rehospitaliza-
tion for heart failure, adjusting echocardiographic variables. In addition,
to adjust for selection bias, propensity scores for each patient were esti-
mated with logistic regression, with HF (+) as the outcome. Twelve
baseline clinical and echocardiographic variables were chosen for
imputation and derivation of propensity scores, based on clinical and
echocardiographic relevance and ability to correct for differences be-
tween HF (+) vs. HF (−) groups. The JMP statistical package (version
11.0, SAS Institute, Inc. Cary, NC, USA) was used for all statistical tests.
A signiﬁcance level of 0.05 was used and two-tailed tests were applied.
3. Results
Flow Chart in this study is shown in Fig. 2. From April 2009 to April
2011, 3D TEEwas performed in 144 patients. Among these, 116 patients
were enrolled in this study. Sixteen patients in whom 3D TEE was per-
formed over 48 h after 2D TTE were not enrolled. Nine patients were
not enrolled because of poor TV visualization (6 patients by 3D TEE
and 3 patients by 2D TTE). Three patients were not enrolled because
of congenital heart disease. Conditions for which 3D TEEwas performed
are summarized in Table 1. Themean LVEF was 58.4% ± 13.5%, ranging
from 15% to 78%. To rule out the presence of left atrial thrombus, 3D TEE
was performed on 60 patients with atrial ﬁbrillation, 2 patients with
atrial ﬂutter, and 10 patients with cerebral infarction which did not
have any severe valvular disease. Left atrial thrombus was not detected
in them. Furthermore, 3D TEE was performed in 4 patients to rule out
infective endocarditis. Mitral valve vegetation was detected in one of
them, but he did not have severe mitral regurgitation. 3D TEE was per-
formed in other patients to assess structural heart disease. Mild mitral
regurgitation was observed in 42 patients (64%), moderate in 21
(32%), and severe in 3 (4%) patients. Patients were classiﬁed into three
groups according to TR grade: the mild TR group (n = 77), moderate
TR group (n = 26), and severe TR group (n = 13). Clinical characteris-
tics by TR grades are shown in Table 2. No signiﬁcant differences in age,
gender, body mass index, body surface area, hypertension, dyslipid-
emia, diabetes mellitus, or chronic kidney disease were observed be-
tween the three groups. A signiﬁcantly higher history of HF was found
in patients with severe TR than in patients with mild and moderate TR
(69% vs. 17%, 42%, respectively; p b 0.05), whereas no signiﬁcant differ-
ence in the N-terminal pro B-type natriuretic peptide (NT-proBNP) was
detected between groups. Table 3A displays 2D TTE ﬁndings by TR
grades. No signiﬁcant differences in LV end-diastolic dimension
(LVDd), LV end-systolic dimension (LVDs), LVEF, or left atrial dimension
(LAD) were observed between the three groups. RVDd, RVDs and RVEF
in patients with severe TR were signiﬁcantly larger than those in pa-
tients with mild and moderate TR (RVDd: 30.1 ± 10.5 mm vs. 20.9 ±
5.5 mm, 20.6 ± 4.6 mm, p b 0.001, RVDs: 25.1 ± 11.2 mm vs. 15.9 ±
4.3 mm, 15.6 ± 4.3 mm, p b 0.001, RVEF: 39.9 ± 13.5% vs. 52.6 ±
11.6%, 52.7 ± 9.9%, p = 0.001; respectively). TA dimension in patients
with severe TR was signiﬁcantly larger than those in patients with
mild and moderate TR (32.9 ± 6.7 mm vs. 23.9 ± 6.0 mm, 22.1 ±
Fig. 1.Measurement of the tricuspid valve (TV). (A) TV image using two-dimensional transesophageal echocardiography. (B) Full-volume imagingwas obtained at the same angle. (C) The
cross-sectional image in the red frame shows the segment from the anteroseptal to the anteroposterior commissure. The cross-sectional image in the green frame shows vertical thinning
from the anterior to the posteroseptal commissure. (D) TV in the cross-sectional image in the blue frame was measured in the end-systolic phase. (E) TV measurement: The tricuspid
annular area (TAA) and 3 intercommissural distances (ICDs) (anterior, posterior, and septal ICD) were measured. Ant. = anterior leaﬂet, Post. = posterior leaﬂet, Sept. = septal leaﬂet.
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signiﬁcantly higher than that in patients with mild and moderate TR
(41.5 ± 11.0 mmHg vs. 29.8 ± 7.1 mmHg, 39.0 ± 11.8 mmHg, respec-
tively; p b 0.05). Table 3B displays 3D TEE ﬁndings by TR grades.
Intraobserver variability was 0.57 ± 0.10 mm2 for TAA. Interobserver
variability was 1.29 ± 0.21 mm2 for TAA. TAA in the severe TR group
was signiﬁcantly larger than that in the mild and moderate TR groups
(18.4 ± 3.8 cm2 vs. 11.7 ± 3.2 cm2, 12.3 ± 3.4 cm2, respectively;p b 0.05, Fig. 3). ICD showed correlation with TAA (anterior ICD: r2 =
0.72, posterior ICD: r2 = 0.53, septal ICD: r2 = 0.48, p b 0.001; respec-
tively). In addition, TA dimension as measured by 2D TTE showed corre-
lation with TAA (r2 = 0.40, p b 0.001). Optimal correlation was found
between anterior ICD and TAA.
During a mean follow-up period of 704 ± 411, 18 patients (15.5%)
were readmitted because of HF aggravation. All patients were not treat-
ed with TAP. Patients were classiﬁed into two groups based on
Fig. 2. Flow Chart in this study. Excluded because of over 48 h after 2D TTE (n= 16), poor visualization (n= 9) and congenital heart disease (n= 3). 3D TEE= three-dimensional trans-
esophageal echocardiography, 2D TTE = two-dimensional transthoracic echocardiography, TR = tricuspid regurgitation, HF = heart failure.
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(n = 18) and HF (−) group (n = 98). Clinical and echocardiographic
characteristics between HF (+) group and HF (−) group are shown in
Table 4. No signiﬁcant differences in age, gender, hypertension, dyslip-
idemia, diabetes mellitus, chronic kidney disease, or NT-proBNP were
observed between the two groups. History of HF was signiﬁcantly
higher in HF (+) group than HF (−) group (50% vs. 24%, p = 0.03).
HF (+) group had 6 patients with mild TR, 4 with moderate TR, and 8
with severe TR. A signiﬁcantly lower LVEF and RVEF were found in
HF (+) group than HF (−) group (LVEF: 46.4 ± 15.1% vs. 60.5 ±
12.1%, p b 0.001, RVEF: 52.3 ± 11.5% vs. 45.1 ± 13.8%, p = 0.047; re-
spectively). TA dimension in HF (+) group was signiﬁcantly larger
than HF (+) group (29.1 ± 8.8 mm vs. 23.7 ± 5.5 mm, p = 0.003).
TAA in HF (+) group was signiﬁcantly larger than HF (+) group
(16.8 ± 4.3 cm2 vs. 11.8 ± 3.3 cm2, p b 0.001; Fig. 4). In receiver oper-
ating characteristics curve assessing the ability of TAA to predict hospi-
talization for HF, the area under the curve of TAA was 0.84 (p= 0.001;
Fig. 5). TAA ≥ 15 cm2 best predicted hospitalization for HF with 77.8%
sensitivity and 84.6% speciﬁcity. LV and RV dysfunction aggravates
TAD. To detect independent effect of TAD for rehospitalization for HF
in echocardiographic parameters, TAA ≥ 15 cm2 as well as presence of
LV dysfunction, RV dysfunction and TA dimension was incorporated to
a Cox proportional hazard model. Univariate analysis revealed that
TAA≥ 15 cm2, TA dimension and RV dysfunction were an independent
predictor for rehospitalization for HF [TAA≥ 15 cm2: hazard ratio (HR)Table 1
Conditions for which 3D TEE was performed.
n = 116
MR 33 (28.4%)
MS 3 (2.6%)
AR 1 (0.9%)
AS 2 (1.7%)
AS + AR 1 (0.9%)
paroxysmal AF 31 (26.7%)
chronic AF 15 (12.9%)
persistent AF 14 (12.1%)
others 16 (13.7%)
OtherswereAFL (n = 2; 1.7%), exclusion of I.E., cardiac tumor
(n = 4; 3.4%), stroke (n = 10; 8.6%).
MR = mitral regurgitation, MS = mitral stenosis, AR =
aortic regurgitation, AS = aortic stenosis, AF = atrial
ﬁbrillation, AFL = atrial ﬂutter, I.E. = infective endocarditis.14.5, 95% conﬁdence interval (CI) 5.10–51.92, p b 0.001, TA dimension:
HR 4.86, 95% CI 2.13–11.35, p b 0.001, RV dysfunction: HR 3.13, 95% CI
1.08–8.15, p = 0.036; respectively, Table 5]. Multivariate analysis re-
vealed that TAA≥ 15 cm2 was an independent predictor for rehospital-
ization for HF [HR 10.3, 95% CI 3.26–38.98, p b 0.001, Table 5]. In
addition, Cox proportional hazard regression analyses of TAA for
rehospitalization for HF after adjustment for propensity scores is
shown in Table 6. After adjusting for age, male, hypertension, dyslipid-
emia, diabetes mellitus, CKD, history of HF, NT-proBNP, TR grade, LVEF,
RVEF and TA dimension using propensity scores, TAA ≥ 15 cm2 was an
independent predictor for rehospitalization for HF [HR 5.19, 95% CI
1.30–22.29, p =0.02]. When TAD (+) was deﬁned as TAA ≥ 15 cm2,
the incidence of hospitalization for HF during 3 years was signiﬁcantly
higher in TAD (+) group than TAD (−) group (48.3% vs 4.6%,
p b 0.001; Fig. 6).4. Discussion
The major ﬁnding of the present study was that TAA assessed by 3D
TEE in the group with severe TRwas signiﬁcantly larger compared with
that in the other groups (mild andmoderate).Moreover, TAD estimated
by 3D TEE may predict hospitalization for prospective HF.
Recently, 3D TEE has been utilized in planning surgical treatment for
valve disease. As the severity of TR is associated with its prognosis [4],Table 2
Clinical Characteristics by TR Grades.
Mild TR
(n = 77)
Moderate TR
(n = 26)
Severe TR
(n = 13)
p value
Age (yr) 60 ± 14 65 ± 15 66 ± 11 0.10
Male 50 (65%) 14 (54%) 7 (54%) 0.51
Body mass index 23.1 ± 3.9 23.2 ± 2.8 22.3 ± 3.9 0.74
Body surface area 1.65 ± 0.24 1.57 ± 0.22 1.52 ± 0.21 0.09
Hypertension 23 (30%) 12 (46%) 6 (46%) 0.22
Dyslipidemia 11 (14%) 6 (23%) 2 (15%) 0.59
Diabetes mellitus 9 (12%) 7 (27%) 1 (8%) 0.15
CKD 24 (31%) 14 (54%) 4 (31%) 0.11
History of HF 13 (17%) 11 (42%) 9 (69%)⁎ b0.001
NT-proBNP
(pg/ml)
550 (147–1909) 1169 (79–2788) 682 (290–3896) 0.48
TR = tricuspid regurgitation, CKD = chronic kidney disease, HF = heart failure, NT-
proBNP = N-terminal pro B-type natriuretic peptide.
⁎ P b 0.05 vs. mild and moderate TR.
Table 3A
2D TTE Findings by TR Grades.
Mild TR
(n = 77)
Moderate TR
(n = 26)
Severe TR
(n = 13)
p value
LVDd (mm) 51.6 ± 7.9 50.3 ± 7.0 51.3 ± 14.0 0.81
LVDs (mm) 34.8 ± 8.7 34.5 ± 6.7 37.1 ± 14.8 0.66
LAD (mm) 43.2 ± 7.8 46.4 ± 7.6 47.7 ± 10.7 0.08
LVEF (%) 58.7 ± 14.2 59.0 ± 10.5 53.8 ± 16.2 0.49
RVDd (mm) 20.9 ± 5.5 20.6 ± 4.6 30.1 ± 10.5⁎ b0.001
RVDs (mm) 15.9 ± 4.3 15.6 ± 4.3 25.1 ± 11.2⁎ b0.001
RVEF (%) 52.6 ± 11.6 52.7 ± 9.9 39.9 ± 13.5⁎ 0.001
TA dimension (mm) 23.9 ± 6.0 22.1 ± 4.3 32.9 ± 6.7⁎ b0.001
PASP (mmHg) 29.8 ± 7.1 39.0 ± 11.8 41.5 ± 11.0⁎ b0.001
TR = tricuspid regurgitation, LVDd = left ventricular end-diastolic dimension, LVDs =
left ventricular end-systolic dimension, LAD = left atrial dimension, LVEF = left ventric-
ular ejection fraction, RVDd = right ventricular end-diastolic dimension, RVDs = right
ventricular end-systolic dimension, RVEF = right ventricular ejection fraction, TA
dimension = tricuspid annular dimension, PASP = pulmonary artery systolic pressure.
⁎ P b 0.05 vs. mild and moderate TR.
Table 3B
3D TEE Findings by TR Grades.
Mild TR
(n = 77)
Moderate TR
(n = 26)
Severe TR
(n = 13)
p value
TAA (cm2) 11.7 ± 3.2 12.3 ± 3.4 18.4 ± 3.8⁎ b0.001
Anterior ICD (mm) 32.7 ± 6.3 33.6 ± 6.6 41.7 ± 5.5⁎ b0.001
Posterior ICD (mm) 27.7 ± 5.8 27.2 ± 5.9 33.6 ± 4.8⁎ 0.002
Septal ICD (mm) 31.6 ± 5.9 30.0 ± 7.2 37.4 ± 8.8⁎ 0.005
TR = tricuspid regurgitation, TAA = tricuspid annular area, ICD = intercommissural
distances.
⁎ P b 0.05 vs. mild and moderate TR.
Table 4
Clinical and Echocardiographic Characteristics between HF (+) and HF (−).
HF (+)
(n = 18)
HF (−)
(n = 98)
p value
Age (yr) 63 ± 13 62 ± 14 0.95
Male 11 (61%) 60 (61%) 0.99
Hypertension 7 (39%) 34 (35%) 0.73
Dyslipidemia 3 (17%) 13 (13%) 0.71
Diabetes mellitus 4 (22%) 13 (13%) 0.34
CKD 5 (28%) 37 (38%) 0.41
History of HF 9 (50%) 24 (24%) 0.03
NT-proBNP (pg/ml) 689 (34–1749) 581 (212–1182) 0.49
TR grade
Mild/Moderate/Severe 6/4/8 71/22/5 b0.001
LVEF (%) 46.4 ± 15.1 60.5 ± 12.1 b0.001
RVEF (%) 45.1 ± 13.8 52.3 ± 11.5 0.047
TA dimension (mm) 29.1 ± 8.8 23.7 ± 5.5 0.003
TAA (cm2) 16.8 ± 4.3 11.8 ± 3.3 b0.001
HF = heart failure, CKD = chronic kidney disease, NT-proBNP = N-terminal pro B-type
natriuretic peptide, TR = tricuspid regurgitation, LVEF = left ventricular ejection
fraction, RVEF = right ventricular ejection fraction, TA dimension = tricuspid annular
dimension, TAA = tricuspid annular area.
174 H. Ikenaga et al. / IJC Heart & Vessels 4 (2014) 170–176TAP is recommended when left-sided valve surgery is necessary in pa-
tients with signiﬁcant functional TR [17]. However, signiﬁcant residual
TR has been reported in 10%–45% of these patients after TAP [5–8,18],
and which patients would develop TR is uncertain. Previous studies
reported that pre-TAP tenting volume, PASP, anteroposterior annulus
diameter, and TAA were independent predictors of residual TR severity
[7,19]. Measurement of these parameters using 3D TEE may help iden-
tify patients at high risk for severe residual TR forwhomTV replacement
may be initially considered.
Fast, noninvasive, and accurate preoperative estimation of TV
morphology in the dynamic state is important for good prognosis. A
previous study reported a good correlation between TA diameter and
TR regurgitant volume as assessed by 2D TEE [20]. TA diameter was
measured at the end diastole from three cross-sectional views obtained
by 2D TEE. This value was deﬁned as the maximum length of TA deter-
mined by the longest distance between the bases of the opposing twoFig. 3. Tricuspid annular area (TAA) in the three groups according to the tricuspid regur-
gitation (TR) grade. TAA in the severe TR group was signiﬁcantly larger than that in the
mild and moderate TR groups (18.4 ± 3.8 cm2 vs. 11.7± 3.2 cm2, 12.3 ± 3.4 cm2, respec-
tively; p b 0.05).leaﬂets in these three views. The ﬁndings in the present studywere con-
sistentwith the results of this previous study. However, evaluation of TA
using 2D echocardiography was insufﬁcient for accurate measurement
of TAD because only two of the three leaﬂets could be visualized on a
single view. In contrast, TA dimensionsweremore accurately evaluated
using 3D TTE than using 2D TTE; these results were compared with
those of magnetic resonance imaging because dynamic visualization of
all three tricuspid leaﬂets and their annular attachments was possible
[21]. The TA may be a 3-dimensional structure like mitral annulus,
which may hamper measuring the tricuspid annular area in a single
cross sectional image. However, it was reported that patients without
TR had a nonplanar shaped TA and patients with severe TR had a
more planar shaped TA [22]. It was thought that TAA in the severe TR
group could be evaluated almost accurately in this study. In addition,
strong correlation with TAA was achieved with anterior ICD measured
by 3D TEE. Imaging was superior using this method to measure TA
dimensions using 2D TTE.
Functional TRwith no deformation of TV is common in patientswith
left-sided valve disease, especially mitral valve disease. More than one-
third of patients withmitral stenosis have at leastmoderate TR [23]. Mi-
tral valve disease leads to increased left atrial pressure and pulmonary
hypertension. Mild and moderate TR is often caused by this afterload.
Likewise, atrial ﬁbrillation and left ventricular diastolic dysfunction
may cause chronic elevation of left atrial pressure and lead to mild
andmoderate TR. Furthermore, in cases of long-term pulmonary hyper-
tension, RV dysfunction and remodeling may progress, leading to TAD,
papillary muscle displacement, tethering of the TV leaﬂets, and, ulti-
mately, severe TR [2,7,20,24].Fig. 4. Tricuspid annular area (TAA) in the two groups based on rehospitalization for heart
failure (HF) after discharge from the hospital. TAA inHF (+) groupwas signiﬁcantly larger
than HF (+) group (16.8 ± 4.3 cm2 vs. 11.8 ± 3.3 cm2, p b 0.001).
Fig. 5. In receiver operating characteristics curve assessing the ability of tricuspid annular
area (TAA) to predict hospitalization for heart failure (HF), the area under the curve of TAA
was 0.84 (p = 0.001). TAA ≥ 15 cm2 best predicted hospitalization for HF with 77.8%
sensitivity and 84.6% speciﬁcity.
Fig. 6. Hospitalization for heart failure (HF) in patients with tricuspid annular dilatation
(TAD) and thosewithout TAD.When TAD (+)wasdeﬁned as TAA≥ 15 cm2, the incidence
of hospitalization for HF during 3 years was signiﬁcantly higher in TAD (+) group than
TAD (−) group (48.3% vs 4.6%, p b 0.001).
175H. Ikenaga et al. / IJC Heart & Vessels 4 (2014) 170–176In this study, no signiﬁcant differences in TAA were identiﬁed be-
tween the mild TR and moderate TR groups. This result supported the
assertion that in a stable state, severe TR does not occur without severe
TAD. In patients with severe TR, PASPwas signiﬁcantly higher than that
in patients withmild TR andmoderate TR. Long-term volume and pres-
sure overload to the left atrium (LA) may have led to LA enlargement
and aggravated PASP. Moreover, long-term RV pressure and volume
overloadmay have led to further RV dilatation and dysfunction, causing
more TAD and TV leaﬂet tethering, and ultimately exacerbating TR [17,
22,25]. Although tenting height and tethering area were not considered
in this study, TAD was strongly associated with TR severity.Table 5
Univariate and Multivariate Predictors for Rehospitalization for Heart Failure.
x2 Hazard ratio 95% CI p value
Univariate analysis
TAA ≧ 15 cm2 27.6 14.5 (5.10–51.92) b0.001
LV dysfunction 3.63 2.78 (0.97–7.17) 0.057
TA dimension (mm) 14.1 4.86 (2.13–11.35) b0.001
RV dysfunction 4.38 3.13 (1.08–8.15) 0.036
Multivariate analysis
TAA ≧ 15 cm2 16.5 10.3 (3.26–38.98) b0.001
LV dysfunction 3.23 2.75 (0.91–7.66) 0.072
TA dimension (mm) 1.89 1.98 (0.75–5.55) 0.17
RV dysfunction 0.01 0.94 (0.26–2.99) 0.93
TAA = tricuspid annular area, LV = left ventricular, LV dysfunction (LV ejection
fraction ≤ 40%), TA dimension = tricuspid annular dimension, RV = right ventricular,
RV dysfunction (RV ejection fraction ≤ 40%), CI = conﬁdence interval.
Table 6
Cox Proportional Hazard Regression Analyses of TAA for Rehospitalization for Heart Fail-
ure After Adjustment for Propensity Scores.
x2 Hazard ratio 95% CI p value
TAA ≧ 15 cm2 5.4 5.19 (1.30–22.29) 0.02
TAA = tricuspid annular area, CI = conﬁdence interval.
Adjusted for age, male, hypertension, dyslipidemia, diabetes mellitus, chronic kidney
disease, history of heart failure.
N-terminal pro B-type natriuretic peptide, tricuspid regurgitation grade, left ventricular
ejection fraction, right ventricular ejection fraction, tricuspid annular dimension.Previous studies have suggested that severe TR was associated with
a poor prognosis and was independent of age, biventricular systolic
function, RV size, and dilation of the inferior vena cava [1]. In the current
study, we evaluated TAA for a prediction of hospitalization for prospec-
tive HF. TADwas a stronger predictor of rehospitalization for HF than TA
dimension, LV dysfunction and RV dysfunction. In addition, TAA of
≥15 cm2 accurately predicted hospitalization for prospective HF in
our study. TAA has clinical importance to estimate the probability of
HF in patients without severe TR because TR is strongly inﬂuenced by
volume and pressure overload. Therefore, tricuspid annular dilatation
should be one of the methods for trigger prophylactic tricuspid valve
repair, regardless of the degree of TR to prevent prospective HF.4.1. Study limitations
The following study limitations should be acknowledged. This
study was conducted retrospectively, based on an echocardiographic
database. In addition, the number of patients included in the study
was relatively small. This study analyzed a highly selected population.
Patients with very poor 3D echocardiographic images were excluded
due to poor visualization of TV at longer distances from TEE, severely
oblique angles, and thinner leaﬂets. This fact may have introduced a se-
lection bias into the results. The TA may be a 3-dimensional structure,
which may hamper measuring the tricuspid annular area in a single
cross sectional image. TAA in the mild and moderate TR groups might
be underestimated.5. Conclusions
The results of this study suggested a possible association between
TAD and the TR grade. In addition, TAD estimated by 3D TEEmay predict
hospitalization for prospective HF. Further studies should be advocated
to investigate the better therapeutic options for these high-risk patients.Conﬂicts of interest
none declared.Acknowledgements
None.
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